Scribd Logo
Upload

Welcome to Scribd!

  • 178 views

    Ranbaxy Laboratories Limited

    Uploaded by

    Rohit
    Ranbaxy Laboratories is India's largest pharmaceutical company, established in 1961. It has a global presence in over 125 countries with manufacturing units in 11 countries and over 12,000 employees worldwide. Ranbaxy specializes in oral drug delivery systems, peptides, anti-infectives, and oncology. It has an active pipeline of new drug candidates and works with other companies through strategic alliances and acquisitions to develop and market drugs globally.

    Copyright:

    Attribution Non-Commercial (BY-NC)
    Download as PPTX, PDF, TXT or read online from Scribd

    Ranbaxy Laboratories Limited

    Uploaded by

    Rohit
    178 views11 pages
    Ranbaxy Laboratories is India's largest pharmaceutical company, established in 1961. It has a global presence in over 125 countries with manufacturing units in 11 countries and over 12,000 employees worldwide. Ranbaxy specializes in oral drug delivery systems, peptides, anti-infectives, and oncology. It has an active pipeline of new drug candidates and works with other companies through strategic alliances and acquisitions to develop and market drugs globally.

    Copyright

    © Attribution Non-Commercial (BY-NC)

    Available Formats

    PPTX, PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    Ranbaxy Laboratories is India's largest pharmaceutical company, established in 1961. It has a global presence in over 125 countries with manufacturing units in 11 countries and over 12,000 employees worldwide. Ranbaxy specializes in oral drug delivery systems, peptides, anti-infectives, and oncology. It has an active pipeline of new drug candidates and works with other companies through strategic alliances and acquisitions to develop and market drugs globally.

    Copyright:

    Attribution Non-Commercial (BY-NC)
    Download as PPTX, PDF, TXT or read online from Scribd
    Download as pptx, pdf, or txt
    178 views11 pages

    Ranbaxy Laboratories Limited

    Uploaded by

    Rohit
    Ranbaxy Laboratories is India's largest pharmaceutical company, established in 1961. It has a global presence in over 125 countries with manufacturing units in 11 countries and over 12,000 employees worldwide. Ranbaxy specializes in oral drug delivery systems, peptides, anti-infectives, and oncology. It has an active pipeline of new drug candidates and works with other companies through strategic alliances and acquisitions to develop and market drugs globally.

    Copyright:

    Attribution Non-Commercial (BY-NC)
    Download as PPTX, PDF, TXT or read online from Scribd
    Download as pptx, pdf, or txt
    of 11

    Ranbaxy Laboratories Limited

    COMMERCIAL PRESENTATION

    -Rohit Shrivastava
    MSc Drug Development with Bio-business
    University of Aberdeen, U K
    Introduction
    Ranbaxy Lab. Ltd is India’s largest
    Pharmaceutical company was established in
    1961. It is a research based International
    company with its headquarters at Gurgaon,
    India.
    Its CEO & Managing Director is Mr. Atul Sobti.
    Global Presence
    • It has been ranked 8thth among the top global generic
    Pharmaceutical companies.
    • It has consumers in over 125 countries and a total revenue of
    $ 1.7 Bn.
    • It is present in 49 countries and has manufacturing units in
    11 countries.
    • It has a strong workforce of more than 12,000 employees.
    Sector

    Ranbaxy specializes in oral delivery systems, peptides , anti-infectives, Oncology


    (through Zenotech ). Active Pharmaceutical ingredients, Dosage forms.

    ●
    Current research is going on taste masking, gels, chewable tablets, effervescent.

    Ranbaxy acquired in-licenses from Ochoa Lab. Ltd for its entire range of
    dermatological and lifestyle products.

    ●
    In-licensed asthetic dermatology products from Darier (Mexico) & Medy tox ( S.
    Korea).
    Alliance and Acquisitions
    • Has active alliances with numerous companies all over the world.

    • Ciprofloxacin oral once daily formulation developed by Ranbaxy was out licensed to
    Bayer AG, Germany to exclusively market the drug for $10Mn and royalties.

    • Alliance with Zenotech increased the foothold in Biopharmaceuticals.

    • Ranbaxy works in alliance with GsK and Merck in the area of New Drug Discovery and
    Clinical Development.

    • Ranbaxy out-licensed its statin molecule to PPD Inc. USA.

    • Acquired generic business of companies in Germany (Bayer), Spain (EFARMES ) &


    (Mundogen), S. Africa (Be Tabs), Italy and Spain (GsK) , Romania (Therapia), Italy (Allen),
    Belgium (Ethimed), USA (Derma brands & Auto-injector Technologies), India (Orchid,
    Zenotech, Krebs, Jupiter & Cardinal Drugs) .
    Business Model
    • Ranbaxy continues to evaluate acquisition opportunities
    in India, emerging & developed market to accentuate its
    business & competitiveness.

    Strength Weakness
    - Low manufacturing - Low investment in
    cost innovative R&D
    - Access to the pool of - Lack of strong links
    highly trained scientist between industry and
    - Presence in global as academia.
    well as emerging - Low healthcare
    market budget

    Threats Opportunities
    - Potential to develop India
    - Exports hampered by as a center for International
    procedural hurdles in clinical trials.
    India and non-tarrif -Potential for drug discovery
    hurdles abroad. and clinical development.
    - Personalized medicine - In-licensing products from
    MNC to market in domestic
    - Fake drugs lead to loss as well as International
    in sales market.
    The Pipeline
    • Ranbaxy’s NDDR program is focused
    on infectious disease, metabolic
    disease, respiratory disease and Oncology.

    • 8 NCE’s in pre clincal development, Phase I & II (2 molecules in collaboration with


    GsK)

    • Potential anti-malarial Arterolane is in Phase III & Clafrinast for respiratory


    inflammation is in Phase II clinical trials.

    • Dyslipidemia RBx 10558 (hyperlipidemia)is in developmental stage. DPP-IV inhibitor


    for Type 2 Diabetes. Phosphodiasterase inhibitor for asthama, novel antibacterials
    for community acquired respiratory infection are in developmental stage.

    • Ranbaxy has filed 5 IND applications in India. 1 IND in UK for anti-malarial drug RBx
    11160.

    • Ranbaxy has 62 product’s ANDA and 16 FTF’s pending for approval worth $50 Billion
    and had a total of 310 approvals during 2009.
    Consumer Healthcare

    • Ranbaxy Global Consumer Healthcare (RGCH) was


    initiated in 2001.
    • RGCH has unique business communication
    platform “The Rainbow Coalition” which involves
    doctors at on end and consumers at the other end.
    • In 2006, RGCH business generated sales of US$ 19
    Mn with a growth of 19%.
    • Over The Counter products-
    – Revital (mineral & vitamin supplements)
    – Chericof (cough syrup)
    – Eat ease (Appetite stimulant)
    Financing & Investment
    • Cash flow from financial institutions, Foreign institutional investors, corporate bodies &
    investment in subsidiary companies.

    • Due upfront payment of $100 Mn and roylaties worldwide from GsK for anti-infectives
    developed by Ranbaxy.

    • Upfront and royalties of undisclosed amount from Merck for anti-fungal and anti-
    bacterial development and clinical trials.

    • Company is registered in Bombay stock exchange and in National stock exchange . Gold
    depository shares are listed on Luxembourg stock exchange.

    • In Q3 FY 2009 report, Ranbaxy has shown net sales of US$ 356 Mn & 13 % growth and
    a profit of US$ 24 Mn.

    • Ranbaxy has entered into strategic alliance with Daiichi Sankyo with Daiichi having
    63.9% of stake in Ranbaxy. This has strengthened balance sheet, de-risked its business,
    widened the market and Ranbaxy will have access to low cost R&D and manufacturing
    facilities.
    Future Aspirations
    • Based on prowess in New Drug Development
    system and NCE Research and one third to one
    fifth cost of developing a new drug in India
    Ranbaxy is focusing on novel therapeutic
    agents.
    • To develop strong presence in developed
    markets.
    • Aspires to be in top 5 global companies.
    Summary
    • Presence across all key developed & emerging
    markets.
    • Strong distribution network.
    • Cost efficient India based Research &
    Development and Manufacturing.
    • Focus on NCE research
    • 8 molecule in pipeline.
    • 10-15 patents each year.
    THANK YOU

    QUESTIONS???

    You might also like